Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy
about
Targeted Therapy in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (LA-R/M HNSCC)Afatinib radiosensitizes head and neck squamous cell carcinoma cells by targeting cancer stem cells.Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized cAfatinib circumvents multidrug resistance via dually inhibiting ATP binding cassette subfamily G member 2 in vitro and in vivo.Combinational therapy of crizotinib and afatinib for malignant pleural mesothelioma.Afatinib in squamous cell carcinoma of the head and neck.Targeting pathways mediating resistance to anti-EGFR therapy in squamous cell carcinoma of the head and neck.[Treatment of head and neck squamous cell carcinoma recurrences and distant metastases: Highlights of the ASCO Meeting 2015].Blocking of the EGFR-STAT3 signaling pathway through afatinib treatment inhibited the intrahepatic cholangiocarcinoma.
P2860
Q26765429-BFCE1ACF-9951-4BD8-BDF0-A628BAD4BB32Q33591405-AF403C2C-0E54-4E82-84E1-DF424151449EQ34896542-0FC7C028-AA8E-408A-AEF4-C3601D744FDDQ35067898-E9F985B1-2E42-475C-87D2-B4073CED246AQ37679984-90995167-29E4-49D0-BADD-5655839285DBQ38829891-07AD28C3-EDE7-4055-A953-47FEADCAB152Q38892486-2ED154CA-528A-4DF9-B48F-F3DDF3ED5F52Q51287468-D2C00992-AF66-473C-BF1D-7A01FE32786CQ55364953-1F791558-DBFA-41FA-BB0F-082DAA09E521
P2860
Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Rationale and design of LUX-He ...... d after platinum-based therapy
@ast
Rationale and design of LUX-He ...... d after platinum-based therapy
@en
type
label
Rationale and design of LUX-He ...... d after platinum-based therapy
@ast
Rationale and design of LUX-He ...... d after platinum-based therapy
@en
prefLabel
Rationale and design of LUX-He ...... d after platinum-based therapy
@ast
Rationale and design of LUX-He ...... d after platinum-based therapy
@en
P2093
P2860
P356
P1433
P1476
Rationale and design of LUX-He ...... d after platinum-based therapy
@en
P2093
Jean-Pascal H Machiels
Makoto Tahara
Robert I Haddad
P2860
P2888
P356
10.1186/1471-2407-14-473
P407
P577
2014-06-28T00:00:00Z
P5875
P6179
1026757724